NeurAxon Announces NXN-188 Phase 2 Data Demonstrating Efficacy In Acute Migraine

Links shared publicly online about this topic.

  • 759
    total visits

NeurAxon Announces NXN-188 Phase 2 Data Demonstrating Efficacy In Acute Migraine

medicalnewstoday.com —

NeurAxon, Inc., announced today Phase 2 clinical study results for NXN-188, a novel, first-in-class treatment with the potential to raise the current standard of care in acute migraine. NXN-188 i

View full resource at medicalnewstoday.com

Tags: Migraine, Headache, Vascular Headache, Phase 2 Clinical Trial

  • Share

Most Recently Shared on November 2, 2010 at 11:59 am By:

Migraine_Wisdom Migraine OW

NeurAxon Announces NXN-188 Phase 2 Data Demonstrating Efficacy In Acute Migraine: NeurAxon, Inc., announced today ... http://bit.ly/dt7DBj

1 year ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Headache News MNT Headache News

MNT Clinical Trials MNT Clinical Trials

NeurAxon Announces NXN-188 Phase 2 Data Demonstrating Efficacy in Acute Migraine | Business Wire

businesswire.com — “NeurAxon announced Phase 2 clinical study results for NXN-188 demonstrating efficacy in acute migraine. Results were presented at the European Headach” View full resource at businesswire.com

  • View Related
  • Share

Most Recently Shared on October 31, 2010 at 3:47 pm By:

Migraine_Wisdom Migraine OW OW Health

NeurAxon Announces NXN-188 Phase 2 Data Demonstrating Efficacy in Acute Migraine: WALTHAM, Mass.--(BUSINESS WIRE)-... http://bit.ly/aFzjto

1 year ago...

Reply

Retweet

Favorite

Advertisement